Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia (Alkermes plc)

(Source: Alkermes plc) Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia -- Potential New Offering Would Expand Range of ARISTADA Doses to Three Interval Options: Once Monthly, Once Every Six Weeks and Once Every Two Months -- -- Notice of Allowance Issued for ARISTADA Patent Application, Extending Expected Protection Into 2035 -- DUBLIN--(BUSINESS WIRE)--Aug. 8, 2016-- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a two-month dosing interval of ARISTADA (aripiprazole lauroxil) extended-release...